# Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

> **NCT05867030** · PHASE1 · WITHDRAWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.**

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** rituximab
- **DRUG:** parsaclisib

## Key facts

- **NCT ID:** NCT05867030
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-07-28
- **Primary completion:** 2029-08-31
- **Final completion:** 2033-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development strategy adjustment
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867030, "Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05867030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*